Immunome (IMNM)Chief Technology Officer bought ~$198K

~$198K

Approx. value · 21K sh @ $9.43

21K

Holds after · shares reported

Traded

Nov 21, 2024

Filed

Nov 25, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 21, 2024 · this disclosureInsiderOfficer purchased ~$198K of IMNM shares in the open market

What came next

1. Nov 21, 2024Insider · 2 peopleInsiders: 2 purchases (~$780K)
2. Nov 22, 2024InsiderCEO purchased ~$332K of IMNM shares in the open market
3. Jan 31, 2025InsiderCEO purchased ~$1.16M of IMNM shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Immunome

For Immunome, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMNM page.

Other recent filings by Philip Tsai, Chief Technology Officer

• SEC Form 4 at Immunome (IMNM)Mar 25, 2025

The full history of Philip Tsai, Chief Technology Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Immunome

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 4Jun 4, 2025
• SEC Form 4Mar 26, 2025
• SEC Form 4Mar 26, 2025

Everything OQRO holds on this company is on its IMNM page.